title: What would you choose? Sertraline or prolonged exposure in community and PTSD treatment seeking women.
abstract: BACKGROUND
  Both sertraline (SER) and prolonged exposure (PE) are empirically supported treatments for chronic posttraumatic stress disorder (PTSD). While efficacious, these treatments are quite different in approach, and such differences may influence both treatment choice and treatment outcome. To date, we know very little about the relative efficacy of pharmacological and psychological treatments for chronic PTSD.
  
  
  METHODS
  In Study 1, we compared rates of treatment choice (SER or PE) in 74 trauma-exposed women. In Study 2, we extended this work to an open-choice treatment trial, in which 31 female assault survivors with chronic PTSD received their choice of SER or PE for ten weeks and were followed over time.
  
  
  RESULTS
  In Study 1 (82%) and Study 2 (74.2%), the majority of women chose PE. In Study 2, both SER and PE evidenced moderate to large unadjusted effect sizes, with evidence of an advantage for PE in propensity adjusted analyses at posttreatment. Women with co-occurring major depressive disorder (MDD) were more likely to choose SER than those without MDD. However, among those with MDD, the advantage of PE was particularly evident.
  
  
  CONCLUSIONS
  Our results highlight the presence of clear treatment preferences for PTSD and their potential impact on outcome. This study underscores the importance of systematic study of patient preferences and encourages a rethinking of one-size fits all approaches to treatment for mental disorders.
authors: Department of Psychology, Case Western Reserve University, Cleveland, Ohio 44106-7123, USA. norah.feeny@case.edu
authors: Norah C
authors: NC
authors: Feeny
authors: Lori A
authors: LA
authors: Zoellner
authors: Matig R
authors: MR
authors: Mavissakalian
authors: Peter P
authors: PP
authors: Roy-Byrne
mesh_terms: D000293:Adolescent; D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use*; D002755:Choice Behavior; D002908:Chronic Disease; D015897:Comorbidity; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000523:psychology / Q000628:therapy; D005260:Female; D006801:Humans; D007171:Implosive Therapy; D007406:Interview, Psychological; D008875:Middle Aged; D010043:Outcome and Process Assessment, Health Care; D010358:Patient Participation; D010555:Personality Inventory / Q000706:statistics & numerical data; D011594:Psychometrics; D020280:Sertraline / Q000627:therapeutic use*; D013313:Stress Disorders, Post-Traumatic / Q000175:diagnosis / Q000523:psychology / Q000628:therapy*; D055815:Young Adult
chemical_list: D000928:Antidepressive Agents; D020280:Sertraline